1. Introduction {#sec1}
===============

Within Scotland lung cancer remains the commonest cause of cancer related death \[[@B1]\]. The prognosis is bleak with the median survival in advanced disease around four months from diagnosis \[[@B1]\]. Survival compares unfavourably with other European countries and the USA \[[@B1], [@B2]\]. It has often been felt that the Scottish lung cancer population has more comorbidity with poorer performance status thus presenting fewer tolerable therapeutic options.

It is difficult to quantify the complex nature of patient frailty to provide a degree of objective assessment of fitness \[[@B3]\] and as a result prediction of survival in patients diagnosed with lung cancer remains problematical. Currently, prognosis is based upon a combination of stage of disease and performance status although other factors such as weight loss have been identified in the advanced cancer setting \[[@B4]--[@B6]\]. However, these host factors (weight loss and performance status) included in clinical decisions are recognised to be subjective in nature.

Recent work shows that the effect of systemic inflammation is detrimental in terms of outcome in cancer in general \[[@B7], [@B8]\] and in lung cancer specifically \[[@B9]--[@B16]\]. The combination of C-reactive protein and albumin when combined to calculate the modified Glasgow Prognostic Score ([Table 1](#tab1){ref-type="table"}) has been previously validated as an independent predictor of survival \[[@B17]\].

The aim of the present study was to examine the clinical utility of this established objective marker of the systemic inflammatory response, the modified Glasgow Prognostic Score (mGPS), as the basis of risk stratification in patients with lung cancer.

2. Patients and Methods {#sec2}
=======================

Four Scottish centres were included in the study: Aberdeen, Glasgow (Stobhill), Inverclyde, and West Fife. Over a defined period from 2005 to 2008 all newly diagnosed lung cancer patients coming through the regional multidisciplinary meetings (MDTs) were included in the study. In total the details of 882 patients were collected prospectively.

At the time of the patient discussion at the MDT annoymised details were entered into a specifically designed Microsoft Access database. Patient demographics and baseline characteristics (age, sex, postcode, and smoking history), PS (at time of presentation in addition to that six months prior to attendance as estimated by clinicians on questioning patients about fitness), weight loss, laboratory parameters (C-reactive protein, albumin, and ventilatory function), tumour stage and histology, and primary treatment proposed by the MDT were all recorded. If the treatment proposed varied from the 2005 Scottish Intercollegiate Guidelines Network (SIGN) guidelines \[[@B18]\] on lung cancer management the reasons why were also recorded (i.e., age, poor PS, comorbidity, size of tumour, etc.). All four MDTs had input from an oncologist and thoracic surgeon and thus we could be confident of accuracy of the clinical management decision. Details of the study design have previously been published \[[@B19]\].

Information on date of death was obtained via survival analysis undertaken by the Information Service Division (ISD) of NHS Scotland. Death records were complete until 1 June 2011, which served as the censor date for those alive.

2.1. Socioeconomic Status {#sec2.1}
-------------------------

Information on patients\' individual educational or occupational social class was not available, and postcode of residence was used to identify the 2006 Scottish Index of Multiple Deprivation (SIMD) ranking as a proxy indicator of their socioeconomic circumstances \[[@B20]\]. The 2006 SIMD is a validated area-based index that uses 37 indicators in seven domains to rank 6505 small geographic areas in Scotland (data zones) from 1 (most deprived) to 6505 (least deprived). These can be subsequently grouped into quintiles, and we used Scottish national quintiles.

2.2. GPS/mGPS {#sec2.2}
-------------

A venous blood sample was obtained at diagnosis for measurement of CRP concentration and albumin. The coefficient of variation for these methods over the range of measurement was less than 5%, as established by routine quality control procedures. The GPS was constructed as previously described ([Table 1](#tab1){ref-type="table"}) \[[@B21], [@B22]\]. In brief, CRP more than 10 mg/L and albumin less than 35 g/dL were each given a score of 1. The GPS was calculated as 0, 1, or 2. Since hypoalbuminaemia alone in the absence of an increased CRP level did not confer a poorer cancer-specific survival in all patients with cancer \[[@B8], [@B22]\], the GPS was modified to assign a score of 0 in patients with hypoalbuminaemia alone ([Table 1](#tab1){ref-type="table"}) \[[@B23]\].

A number of recent studies have supported the use of mGPS in predicting outcome both in lung cancer and other tumour types \[[@B9]--[@B17]\]. As such it was our intention to stratify the group by mGPS and then analyse the impact of more conventional staging methods such as TNM stage and performance status.

2.3. Ethics {#sec2.3}
-----------

The audit was discussed with the local ethics committee, and since it was classed as a health service clinical practice audit, formal ethical approval was deemed not to be necessary.

2.4. Statistics {#sec2.4}
---------------

All statistical testing was conducted at the 5% level so 95% confidence intervals (CI) are reported throughout. Unless otherwise stated, medians and interquartile range (IQR) are used. The survival time defined as the number of months from study entry until death or if alive at follow-up date was calculated. Univariate survival analysis was carried out using the Kaplan-Meier method and the log rank test. Survival analysis was carried out using Cox\'s proportional-hazards model and hazard ratios (HR) were calculated. Multivariate survival analysis was performed using a stepwise backward procedure to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding *P* value had to be \>0.10.

Statistical analyses were performed using SPSS v19.0 (SPSS Inc., Chicago, IL).

3. Results {#sec3}
==========

In total, 882 patients from a number of different treatment groups were included in the study, comprising 297 from Aberdeen, 136 from West Fife, 285 from Glasgow, and 164 from Inverclyde composing; 59 patients were excluded from the study due to missing survival data ([Figure 1](#fig1){ref-type="fig"}). Baseline characteristics are shown in [Table 2](#tab2){ref-type="table"}. The median age of participants was 72 years old. The majority were male, current or ex-smokers, and of good performance status with advanced disease and had treatment with palliative intent.

Of the patients 24% were diagnosed on the basis of clinical examination and radiological investigations alone and without histological evidence. This compares favourably with the National Lung Cancer Audit data \[[@B24]\], which had a median rate of 37% of patients who did not have histological confirmation of lung cancer.

Most had an elevated mGPS. The median followup for survivors was 24.5 months (4.6--40.8). The median overall survival was 5.6 months (4.8--6.5). The 12-month survival rate was 30% (SE 2%).

Survival analysis using both GPS and mGPS was undertaken (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Both were highly significantly associated with survival. Since the mGPS has been most extensively validated and readily extrapolated from previous work using C-reactive protein alone \[[@B7], [@B17]\], it was used in the remainder of the analysis and to stratify the three groups.

The relationship between the mGPS and clinicopathological characteristics is shown in [Table 3](#tab3){ref-type="table"}. There were 213 patients in the mGPS score of 0 group, 290 patients in the mGPS score of 1 group, and 218 patients in the mGPS score of 2 group. The mGPS was associated with increasing deprivation (*P* \< 0.001), pack years smoking (*P* \< 0.001), poorer performance status (*P* \< 0.001), more weight loss (*P* \< 0.001), more advanced disease (*P* \< 0.001), more radical treatment (*P* \< 0.001), and poorer survival (*P* \< 0.001).

The relationship between the clinicopathological characteristics and survival in patients with an mGPS of 0 is shown in [Table 4](#tab4){ref-type="table"}. The median survival was 13.2 (11.2--18.9) months. On univariate survival analysis, performance status (*P* \< 0.001), weight loss (*P* \< 0.01), stage of NSCLC (*P* \< 0.001), radical treatment offered (*P* \< 0.01), and palliative treatment offered (*P* \< 0.05) were significantly associated with survival. On multivariate analysis, performance status (HR 1.69, 95% CI 1.39--2.06, and *P* \< 0.001), weight loss (HR 1.18, 95% CI 1.04--1.33, and *P* = 0.009), stage of NSCLC (HR 1.06, 95% CI 1.01--1.23, and *P* = 0.017) and palliative treatment offered (HR 1.30, 95% CI 1.08--1.55, and *P* = 0.004) were independently associated with survival.

The relationship between the clinico-pathological characteristics and survival in patients with an mGPS of 1 is shown in [Table 5](#tab5){ref-type="table"}. The median survival was 6.1 (4.9--7.3) months. On univariate survival analysis, decreased age (*P* \< 0.01), performance status (*P* \< 0.001), weight loss (*P* \< 0.01), stage of NSCLC (*P* \< 0.001), and radical treatment offered (*P* \< 0.001) were significantly associated with survival. On multivariate analysis, performance status (HR 1.81, 95% CI 1.55--2.13, and *P* \< 0.001), stage of NSCLC (HR 1.08, 95% CI 1.03--1.13, and *P* \< 0.01) and radical treatment offered (HR 0.70, 95% CI 0.52--0.94, and *P* \< 0.05) were independently associated with survival.

The relationship between the clinico-pathological characteristics and survival in patients with an mGPS of 2 is shown in [Table 6](#tab6){ref-type="table"}. The median survival was 2.1 (1.5--2.7) months. On univariate survival analysis, centre (*P* \< 0.01), performance status (*P* \< 0.001), weight loss (*P* \< 0.001), stage of NSCLC (*P* \< 0.001), and radical treatment offered (*P* \< 0.01) were significantly associated with survival. On multivariate analysis, only performance status (HR 1.44, 95% CI 1.21--1.71, and *P* \< 0.001) and weight loss (HR 1.13, 95% CI 1.00--1.28, and  *P* \< 0.05) were independently associated with survival.

The relationship between mGPS, performance status, and survival at 1 year is shown in [Table 7](#tab7){ref-type="table"}. When used in combination survival at 1 year varied from 72% (mGPS 0, PS 0) to 6% (mGPS 2, PS 3). The numbers in the PS 4 subgroup were too small to calculate accurately a survival rate.

The relationship between mGPS, TNM stage (NSCLC patients only), and survival at 1 year is shown in [Table 8](#tab8){ref-type="table"}. Survival varied from 69% (mGPS 0, Stage I NSCLC) to 2% (mGPS 2, Stage IV NSCLC).

To stratify for stage, the relationship between mGPS and PS and survival at 3 months for those patients with advanced NSCLC (St IIIb/IV) is shown in [Table 9](#tab9){ref-type="table"}.

Survival varied from 100% (mGPS 0, PS 0) to 23% (mGPS 2, PS 3). The number of patients in the PS 4 group was too small to accurately calculate survival.

This group was then further stratified to take into account the treatment offered. The relationship between mGPS and PS at 3 months for those patients with advanced NSCLC (St IIIb/IV) undergoing palliative chemotherapy is shown in [Table 10](#tab10){ref-type="table"}. Survival varied from 92% (mGPS 0, PS 1) to 50% (mGPS 2, PS 2). The numbers of patients in the PS 0 and 4 groups were too small to accurately calculate survival.

4. Discussion {#sec4}
=============

The results of the present study show for the first time that, in a large cohort of patients with lung cancer and using the mGPS as an objective basis for the prediction of survival, significant factors associated with survival varied significantly. Only performance status and to a lesser extent tumour stage were consistently shown to have independent prognostic value. Furthermore, the combination of the mGPS with either performance status or tumour stage effectively stratified the likely outcome in these patients. Therefore, this simple scheme based on objective criteria provides a new readily applicable approach to the routine clinical evaluation of patients with lung cancer.

In the present study it was of interest that weight loss, a well recognised poor prognostic factor, was inconsistently prognostic when included in the analysis with mGPS and performance status. This may suggest that much of the prognostic value of weight loss is attributable to the activation of the systemic inflammatory response and to the progressive loss of lean tissue leading to nutritional and functional decline \[[@B7]\]. Indeed, activation of the systemic inflammatory response resulted in a marked reduction in median survival of 13 months (mGPS 0) to 2 months (mGPS 2) independent of treatment received. This would suggest that the allocation of treatment was suboptimal and it may be that treatment allocated on a more objective scheme as proposed above will result in improved outcomes in all patients. For example, in those patients with mGPS of 2, neither stage nor treatment had independent prognostic value and therefore it would appear that such poor prognosis patients derive little benefit from standard anticancer treatment. In particular a very honest appraisal of both benefits and toxicities of any treatment should be made with the patient irrespective of their tumour stage \[[@B25]\]. However it must be noted that the very small numbers of patients in these groups (e.g., only 2 patients underwent surgery and 4 underwent radical radiotherapy) make it very difficult to interpret and further studies looking only at radically treatable patients are advised.

The relationship between poor survival and systemic inflammation (the mGPS) remains poorly understood, but it is likely to represent an objective marker of the chronic activation of the innate immune response with the consequent up-regulation of proinflammatory cytokines and growth factors and the resultant cancer cachexia \[[@B26]--[@B31]\].

It is clear that, in Scotland, lung cancer continues to confer a very poor outcome with a median life expectancy of approximately 5 months. Even in early disease (TNM I/II NSCLC), with patients undergoing radical treatment with an expectation of cure (10--15% of total number of patients within Scotland \[[@B32]\]) the 5-year survival is only around 30--60% \[[@B32]\]. The advent of more advanced imaging modalities such as PET-CT \[[@B18]\] has improved detection of occult metastasis leading to stage migration and less patients undergoing futile radical local treatment. Nevertheless, the present results highlight the importance of also staging the host systemic inflammatory response. The mGPS is a simple, cheap, and reproducible prognostic tool that has been shown to be a rational starting point for such work.

Since the initial work, a decade ago the combination of C-reactive protein and albumin, the Glasgow Prognostic Score (GPS/mGPS), has been shown to have independent prognostic value in more than 60 studies (\>30,000 patients with cancer). This prognostic value has been demonstrated in a variety of clinical scenarios, in particular primary operable cancer \[[@B17]\].

A more recent study of apporximately 2,500 patients \[[@B33]\] and this present study have demonstrated that the mGPS has also clinical utility, together with performance status, in patients with advanced cancer.

In conclusion, the results of the present study confirm the independent prognostic value of the mGPS. In addition, it demonstrates the clinical utility of the mGPS combined with performance status to provide more objective risk stratification in patients diagnosed with lung cancer.
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###### 

The Glasgow Prognostic Scores (online only).

                                             Score
  ------------------------------------------ -------
  Glasgow Prognostic Score (GPS)              
   CRP ≤10 mg/L and albumin ≥35 g/L          0
   CRP \>10 mg/L or albumin \<35 g/L         1
   CRP \>10 mg/L and albumin \<35 g/L        2
  Modified Glasgow Prognostic Score (mGPS)    
   CRP ≤10 mg/L and albumin ≥35 g/L          0
   CRP ≤10 mg/L and albumin \<35 g/L         0
   CRP \>10 mg/L                             1
   CRP \>10 mg/L and albumin \<35 g/L        2

###### 

Baseline characteristics of patients with lung cancer (*n* = 882).

  Parameter                        
  ------------------------------- -------------------
  Age (years)                     72 (31--94) years
  Sex                              
   Male                           487 (55%)
   Female                         395 (45%)
  Smoking                          
   Ever smoked                    94%
  Mean pack (years)               44 years
  Centre                           
   Aberdeen                       294 (34%)
   Fife                           132 (15%)
   Stobhill                       245 (32%)
   Inverclyde                     161 (19%)
  Deprivation (quintile)           
   Most deprived                  267 (30%)
   2.00                           127 (14%)
   3.00                           251 (29%)
   4.00                           175 (20%)
   Most affluent                  62 (7%)
  Performance status               
   0                              101 (11%)
   1                              312 (35%)
   2                              285 (32%)
   3                              154 (17%)
   4                              30 (3%)
  Stage                            
   NSCLC I                        66 (7%)
   NSCLC II                       43 (5%)
   NSCLC St IIIa                  48 (5%)
   NSCLC St IIIb                  140 (16%)
   NSCLC St IV                    234 (26%)
   SCLC limited                   33 (4%)
   SCLC extensive                 82 (9%)
   No histology                   210 (24%)
  Treatment                        
   Radical                        193 (27%)
   Palliative                     533 (73%)
  mGPS                             
   0                              213 (24%)
   1                              290 (32%)
   2                              210 (24%)
  Missing data                    169 (19%)
  12-month survival rate % (SE)   30% (2)

###### 

The relationship between the mGPS and clinicopathological characteristics in patients with lung cancer.

  Demographic                     mGPS             *P* value (chi-square test)                    
  ------------------------------- ---------------- ----------------------------- ---------------- ---------
  Age                                                                                              
   \<60/60--69/70--79/≥80 years   33/71/89/28      44/87/119/54                  34/57/91/49      0.064
  Sex                                                                                              
   Male/female                    115/108          174/130                       133/98           0.201
  Centre                                                                                           
   Aber/Fife/Stob/Inver           98/10/77/38      146/25/66/67                  43/16/126/46     \<0.001
  Deprivation                                                                                      
    Most-least (quintile)         68/24/71/39/21   75/47/75/77/30                111/21/70/20/9   \<0.001
  Smoke (pack years)                                                                               
    NS/\<20/20--60/\>60           21/24/126/37     11/33/177/69                  13/21/128/57     0.014
  Performance status                                                                               
   0/1/2/3/4                      42/96/60/22/3    26/130/105/40/3               5/51/88/66/21    \<0.001
  Weight loss (%)                                                                                  
    0/\<5/5--10/\>10              147/24/12/38     146/36/13/109                 79/45/33/73      \<0.001
  FEV1 (%)                                                                                         
   \<80/61--80/40--60/\<40        138/31/45/7      181/48/53/22                  130/33/47/17     0.126
  Local symptoms                                                                                   
   No/yes                         36/127           18/222                        29/137           0.246
  Tumour stage of NSCLC                                                                            
    I/II/IIIa/IIIb/IV             32/11/7/38/38    15/19/20/56/84                7/5/12/36/79     \<0.001
  Tumour stage of SCLC                                                                             
   Limited/extensive              13/21            10/32                         8/18             0.471
  Treatment                                                                                        
   Radical treatment                                                                               
    Surgery/RT/no active          26/9/38          17/15/43                      4/2/18           \<0.001
   Palliative treatment                                                                            
    Chemo/RT/No active            63/27/49         107/58/55                     50/49/75         \<0.001
  Survival                                                                                         
   Alive/dead                     34/181           16/274                        8/211            0.003
   12-month survival % (SE)       46 (4)           16 (2)                        14 (3)           \<0.001

###### 

The relationship between parameters and survival in patients with mGPS = 0 (*n* = 213).

  Parameter                                                   Patients         Univariate          Multivariate                       
  ----------------------------------------------------------- ---------------- ------------------- -------------- ------------------- ---------
  Age                                                                                                                                  
   \<60/60--69/70--79/≥80 years                               33/71/89/28      1.16 (0.98--1.37)   0.077          ---                  
  Sex                                                                                                                                  
   Male                                                       115              1                   ---            ---                 ---
   Female                                                     108              0.81 (0.61--1.09)   0.169          ---                 ---
  Centre                                                                                                                               
   Aberdeen                                                   98               1                   0.068          ---                 ---
   Fife                                                       10               2.72 (1.40--5.29)   ---            ---                 ---
   Stobhill                                                   77               1.00 (0.72--1.41)   ---            ---                 ---
   Inverclyde                                                 38               1.13 (0.75--1.70)   ---            ---                 ---
  Deprivation (most deprived = 1, least deprived = 5)                                                                                  
   1/2/3/4/5                                                  68/24/71/39/21   0.94 (0.85--1.05)   0.299          ---                 ---
  Smoking history (NS = never smoker, otherwise pack years)                                                                            
   NS/\<20/20--60/\>60                                        21/24/126/37     0.93 (0.77--1.12)   0.467          ---                 ---
  Performance status                                                                                                                   
   0/1/2/3/4                                                  42/96/60/22/3    1.76 (1.47--2.11)   \<0.001        1.69 (1.39--2.06)   \<0.001
  Weight loss (% body weight)                                                                                                          
   0/\<5/5--10/\>10                                           147/24/12/38     1.21 (1.08--1.37)   0.002          1.18 (1.04--1.33)   0.009
  FEV1 (%)                                                                                                                             
   \>80/80--60/59--40/\<40                                    138/31/45/7      0.94 (0.80--1.12)   0.515          ---                 ---
  Local symptoms                                                                                                                       
   No/yes                                                     36/127           1.38 (0.91--2.09)   0.124          ---                 ---
  Stage                                                                                                                                
   NSCLC                                                                                                                               
    I/II/IIIa/IIIb/IV                                         32/11/7/38/38    1.38 (1.25--1.53)   \<0.001        1.06 (1.01--1.23)   0.017
   SCLC                                                                                                                                
    Limited/extensive                                         13/21            1.05 (0.97--1.14)   0.228          ---                 ---
  Treatment                                                                                                                            
   Radical                                                                                                                             
    BSC/surgery/RT                                            37/26/8          0.61 (0.48--0.78)   0.001          ---                 ---
   Palliative                                                                                                                          
    Chemo/RT/BSC                                              59/27/47         1.22 (1.01--1.46)   0.039          1.30 (1.08--1.55)   0.004

###### 

The relationship between parameters and survival in patients with mGPS = 1 (*n* = 290).

  Parameter                                                        Patients          Univariate          Multivariate                       
  ---------------------------------------------------------------- ----------------- ------------------- -------------- ------------------- ---------
  Age                                                                                                                                        
    \<60/60--69/70--79/≥80                                         33/71/89/28       1.24 (1.09--1.40)   0.001          ---                 ---
  Sex                                                                                                                                        
   Male                                                            174               1                   0.171          ---                 ---
   Female                                                          130               0.84 (0.66--1.08)   ---            ---                 ---
  Centre                                                                                                                                     
   Aberdeen                                                        145               1                   0.425          ---                 ---
   Fife                                                            23                0.89 (0.55--1.43)   ---            ---                 ---
   Stobhill                                                        55                0.99 (0.72--1.36)   ---            ---                 ---
   Inverclyde                                                      67                1.23 (0.92--1.66)   ---            ---                 ---
  Deprivation (quintile) (most deprived = 1, least deprived = 5)                                                                             
   1/2/3/4/5                                                       75/47/75/77/30    0.99 (0.90--1.08)   0.777          ---                 ---
  Smoking history (NS = never smoker, otherwise pack years)                                                                                  
   NS/\<20/20--60/\>60                                             11/33/177/69      1.02 (0.86--1.22)   0.792          ---                 ---
  Performance status                                                                                                                         
   0/1/2/3/4                                                       26/130/105/40/3   1.83 (1.57--2.14)   \<0.001        1.81 (1.55--2.13)   \<0.001
  Weight loss (% body weight)                                                                                                                
   0/\<5/5--10/\>10                                                181/48/53/22      1.15 (1.06--1.25)   0.001          ---                 ---
  FEV1 (%)                                                                                                                                   
   \>80/80--60/59--40/\<40                                         138/31/45/7       0.94 (0.83--1.06)   0.313          ---                 ---
  Local symptoms                                                                                                                             
   No/yes                                                          18/222            1.60 (0.91--2.80)   0.105          ---                 ---
  Stage                                                                                                                                      
   NSCLC                                                                                                                                     
    I/II/IIIa/IIIb/IV                                              15/19/20/56/84    1.31 (1.19--1.45)   \<0.001        1.08 (1.03--1.13)   0.002
   SCLC                                                                                                                                      
    Limited/extensive                                              10/32             0.51 (0.23--1.11)   0.091          ---                 ---
  Treatment                                                                                                                                  
   Radical                                                                                                                                   
    BSC/surgery/RT                                                 43/17/15          0.55 (0.41--0.72)   \<0.001        0.70 (0.52--0.94)   0.017
   Palliative                                                                                                                                
    Chemo/RT/BSC                                                   107/58/55         1.07 (0.90--1.26)   0.436          ---                 ---

###### 

The relationship between parameters and survival in patients with mGPS = 2 (*n* = 218).

  Parameter                                                        Patients         Univariate          Multivariate                                     
  ---------------------------------------------------------------- ---------------- ------------------- -------------- ------------------- --------- --- ---
  Age                                                                                                                                                     
   \<60/60--69/70--79/≥80                                          34/57/91/49      1.13 (0.98--1.30)   0.084          ---                 ---           
  Sex                                                                                                                                                     
   Male                                                            133              1                   0.136          ---                 ---           
   Female                                                          98               0.81 (0.61--1.07)   ---            ---                 ---           
  Centre                                                                                                                                                  
   Aberdeen                                                        43               1                   0.002          ---                 ---           
   Fife                                                            16               1.71 (0.95--3.06)   ---            ---                 ---           
   Stobhill                                                        114              0.64 (0.45--0.92)   ---            ---                 ---           
   Inverclyde                                                      45               0.88 (0.57--1.35)   ---            ---                 ---           
  Deprivation (quintile) (most deprived = 1, least deprived = 5)                                                                                         
   1/2/3/4/5                                                       111/21/70/20/9   1.05 (0.94--1.17)   0.408          ---                 ---           
  Smoking history (NS = never smoker, otherwise pack years)                                                                                              
   NS/\<20/20--60/\>60                                             13/21/128/57     0.83 (0.69--1.00)   0.062          ---                 ---           
  Performance status                                                                                                                                     
   0/1/2/3/4                                                       5/51/88/66/21    1.51 (1.30--1.76)   \<0.001        1.44 (1.21--1.71)   \<0.001       
  Weight loss (% body weight)                                                                                                                            
   0/\<5/5--10/\>10                                                79/45/33/73      1.25 (1.11--1.40)   \<0.001        1.13 (1.00--1.28)   0.047         
  FEV1 (%)                                                                                                                                               
   \>80/80--60/59--40/\<40                                         130/33/47/17     0.88 (0.77--1.01)   0.073          ---                 ---           
  Local symptoms                                                                                                                                         
   No/Yes                                                          29/137           1.51 (0.98--2.33)   0.063          ---                 ---           
  Stage                                                                                                                                                  
   NSCLC                                                                                                                                                 
    I/II/IIIa/IIIb/IV                                              7/5/12/36/79     1.32 (1.15--1.50)   \<0.001        ---                 ---           
   SCLC                                                                                                                                                  
    Limited/extensive                                              8/18             1.01 (0.91--1.12)   0.826          ---                 ---           
  Treatment                                                                                                                                              
   Radical                                                                                                                                               
    BSC/surgery/RT                                                 18/2/4           0.52 (0.33--0.83)   0.006          ---                 ---           
   Palliative                                                                                                                                            
    Chemo/RT/BSC                                                   50/49/75         0.92 (0.78--1.10)   0.364          ---                 ---           

###### 

The relationship between mGPS and PS and 12-month survival rate (%, SE).

  PS                         mGPS      Total number of patients              
  -------------------------- --------- -------------------------- ---------- -----
  0                          72% (7)   50% (10)                   20% (18)   71
  1                          65% (5)   31% (4)                    30% (7)    259
  2                          49% (7)   19% (4)                    16% (4)    245
  3                          9% (6)    5% (4)                     6% (3)     122
  4                          NC        NC                         NC         20
  Total number of patients   212       290                        218        ---

NC: not calculated where *N* \< 10.

###### 

The relationship between mGPS and TNM stage (NSCLC only) and 12-month survival rate (%, SE).

  Stage                      mGPS       Total number of patients             
  -------------------------- ---------- -------------------------- --------- -----
  I                          69% (19)   28% (12)                   NC        62
  II                         37% (14)   17% (9)                    NC        47
  IIIa                       20% (13)   42% (10)                   0%        53
  IIIb                       20% (6)    6% (3)                     14% (5)   154
  IV                         5% (3)     4% (2)                     2% (2)    261
  Total number of patients   153        225                        173       ---

NC: not calculated where *N* \< 10.

###### 

The relationship between mGPS and PS and 3-month survival rate (%, SE) in patients with TNM stage IIIb/IV NSCLC (*n* = 374).

  PS                         mGPS       Total number of patients              
  -------------------------- ---------- -------------------------- ---------- -----
  0                          100% (0)   92% (8)                    100% (0)   28
  1                          94% (4)    73% (6)                    55% (9)    119
  2                          65% (11)   62% (7)                    43% (8)    105
  3                          NC         29% (11)                   23% (8)    55
  4                          NC         NC                         NC         7
  Total number of patients   61         134                        111        ---

NC: not calculated where *N* \< 10.

###### 

The relationship between mGPS and PS and 3-month survival rate (%, SE) in patients with TNM stage IIIb/IV NSCLC and receiving palliative chemotherapy (*n* = 138).

  PS                         mGPS      Total number of patients              
  -------------------------- --------- -------------------------- ---------- -----
  0                          NC        NC                         NC         13
  1                          92% (7)   74% (8)                    54% (14)   60
  2                          NC        69% (12)                   50% (16)   33
  3                          NC        NC                         NC         12
  4                          NC        NC                         NC         0
  Total number of patients   27        61                         30         ---

NC: not calculated where *N* \< 10.

[^1]: Academic Editor: Seiji Niho
